Skip to main content
. Author manuscript; available in PMC: 2016 Nov 8.
Published in final edited form as: Eur J Gynaecol Oncol. 2013;34(2):113–119.

Table 4.

Adverse events documented during treatment

Bevacizumab
n = 32
Chemotherapy
n = 32
p value
Bleeding 2 (6.3%) 0 0.15
VTE (during treatment) 2 (6.3%) 4 (13%) 0.39
Bowel obstruction 9 (28%) 10 (31.2%) 0.40
Hypertension 7 (22%) 0 0.005
Fistula 1 (3%) 2 (6.3%) 0.55